Next Article in Journal
Colorectal Cancer Patients Have Four Specific Bacterial Species in Oral and Gut Microbiota in Common—A Metagenomic Comparison with Healthy Subjects
Next Article in Special Issue
The Origin of Stroma Influences the Biological Characteristics of Oral Squamous Cell Carcinoma
Previous Article in Journal
Differential Regulation of Lacto-/Neolacto- Glycosphingolipid Biosynthesis Pathway Reveals Transcription Factors as Potential Candidates in Triple-Negative Breast Cancer

Organ-Specific, Fibroblast-Derived Matrix as a Tool for Studying Breast Cancer Metastasis

Biotech Research and Innovation Centre (BRIC), University of Copenhagen (UCPH), 2200 Copenhagen, Denmark
Department of Biotechnology and Biomedicine, Technical University of Denmark, 2800 Lyngby, Denmark
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Academic Editor: Huey-Jen Lin
Cancers 2021, 13(13), 3331;
Received: 6 May 2021 / Revised: 5 June 2021 / Accepted: 25 June 2021 / Published: 2 July 2021
Cancer in the breast often spreads to other parts of the body, such as the lungs, which leads to poor outcomes for patients, as there are few effective treatments. Within organs such as the lungs, cancer cells are surrounded by a scaffold, made of proteins, which helps keeps the organs’ structure and maintains their function. This scaffold is produced by cells called fibroblasts, and we can reproduce this in the lab. We aim to investigate how cancer cells interact with the protein scaffold from different organs, where breast cancer cells spread to. This study hopes to reveal how breast cancer reacts to different organ environments and use this method to perform large-scale drug screening. Importantly, this study has shown that drug testing of breast cancer cells within a more physiological context, as opposed to testing on plastic, can lead to increased identification of targets to treat breast cancer.
During the metastatic process, breast cancer cells must come into contact with the extra-cellular matrix (ECM) at every step. The ECM provides both structural support and biochemical cues, and cell–ECM interactions can lead to changes in drug response. Here, we used fibroblast-derived ECM (FDM) to perform high throughput drug screening of 4T1 breast cancer cells on metastatic organ ECM (lung), and we see that drug response differs from treatment on plastic. The FDMs that we can produce from different organs are abundant in and contains a complex mixture of ECM proteins. We also show differences in ECM composition between the primary site and secondary organ sites. Furthermore, we show that global kinase signalling of 4T1 cells on the ECM is relatively unchanged between organs, while changes in signalling compared to plastic are significant. Our study highlights the importance of context when testing drug response in vitro, showing that consideration of the ECM is critically important. View Full-Text
Keywords: fibroblast-derived matrix; cancer; drug screening fibroblast-derived matrix; cancer; drug screening
Show Figures

Graphical abstract

MDPI and ACS Style

Jensen, A.R.D.; Horton, E.R.; Blicher, L.H.; Pietras, E.J.; Steinhauer, C.; Reuten, R.; Schoof, E.M.; Erler, J.T. Organ-Specific, Fibroblast-Derived Matrix as a Tool for Studying Breast Cancer Metastasis. Cancers 2021, 13, 3331.

AMA Style

Jensen ARD, Horton ER, Blicher LH, Pietras EJ, Steinhauer C, Reuten R, Schoof EM, Erler JT. Organ-Specific, Fibroblast-Derived Matrix as a Tool for Studying Breast Cancer Metastasis. Cancers. 2021; 13(13):3331.

Chicago/Turabian Style

Jensen, Adina R.D., Edward R. Horton, Lene H. Blicher, Elin J. Pietras, Cornelia Steinhauer, Raphael Reuten, Erwin M. Schoof, and Janine T. Erler. 2021. "Organ-Specific, Fibroblast-Derived Matrix as a Tool for Studying Breast Cancer Metastasis" Cancers 13, no. 13: 3331.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop